Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
R&D

China’s Life Expectancy on Track to Surpass 81.3 Years by 2035, Study Reveals

Fineline Cube Apr 3, 2023

A recent study published in The Lancet has provided updated forecasts for life expectancy in...

Company Deals

Willingmed Secures Series B Funding to Advance Clinical Infection Diagnostics

Fineline Cube Apr 3, 2023

Willingmed, a Beijing-based company specializing in molecular biology for clinical infection precision diagnosis, has reportedly...

Policy / Regulatory

CDE Launches Guidelines to Expedite Pediatric and Rare Disease Drug Reviews

Fineline Cube Apr 3, 2023

The Center for Drug Evaluation (CDE) has unveiled a new set of “Work Specifications to...

Company Drug

Johnson & Johnson’s Talquetamab on Track for Breakthrough Therapy Designation in Multiple Myeloma

Fineline Cube Apr 3, 2023

China’s Center for Drug Evaluation (CDE) has indicated that US pharmaceutical giant Johnson & Johnson’s...

Company Drug

CSPC Pharmaceutical Receives FDA Approval for Phase I Study of CPO301 in Lung Cancer

Fineline Cube Apr 3, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Approval for FCN-338 Phase II Study

Fineline Cube Apr 3, 2023

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced receiving approval...

Company Drug

Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Prolia

Fineline Cube Apr 3, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving market approval from the...

Company Drug

Roche’s Cosentyx 300mg Dosage Approved by NMPA for Ankylosing Spondylitis Treatment

Fineline Cube Apr 3, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Changzhou Qianhong Bio-pharma Receives NMPA Approval for QHRD107 Phase II AML Study

Fineline Cube Apr 3, 2023

China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced obtaining approval from the National...

Company Drug

Konruns Pharmaceutical Reports Positive Efficacy Results for KC1036 in Advanced ESCC

Fineline Cube Apr 3, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the publication of efficacy study results...

Company Deals

Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation

Fineline Cube Apr 3, 2023

The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership...

Company Drug

Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis

Fineline Cube Apr 3, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a...

Company Drug

Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012

Fineline Cube Apr 3, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan...

Company

Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization

Fineline Cube Apr 3, 2023

China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached...

Company

Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates

Fineline Cube Mar 31, 2023

China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key...

Company Deals Digital

ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector

Fineline Cube Mar 31, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has...

Company Deals

Pharmaron Secures UK Government Grant to Expand Viral Vector Manufacturing Facility

Fineline Cube Mar 31, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...

Company Drug

HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC

Fineline Cube Mar 31, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling...

Company Deals

Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’

Fineline Cube Mar 31, 2023

Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the...

Company Drug

Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Mar 31, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...

Posts pagination

1 … 536 537 538 … 660

Recent updates

  • GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership
  • AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength
  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

Others

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.